UNSPSC 51333416: Ziprasidone mesilate or mesylate

This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS.CH4O3S.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X6SAX83JZ, chemically known as 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-, methanesulfonate, hydrate (1:1:3), but more generally known as ziprasidone mesylate, which bears US NIH Compound Identifier 154068.

European Medicines Agency schedules ziprasidone mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00168MIG. Most nations, for tariff purposes, schedule ziprasidone mesylate under HS 29341000. Ziprasidone mesylate bears US NLM identifiers UMLS ID C1170754 and NCI Concept Code C48032. SMILES: CS(=O)(=O)O.C1CCC2C(C1)C(NS2)N3CCN(CC3)CCC4CC5C(CC4CL)NC(=O)C5.O.O.O.

UNSPSC 51333416 Ziprasidone mesilate or mesylate is a Commodity code for a specific antipsychotic pharmaceutical, but recent state and local procurement activity under this code shows a sharp mismatch: the only recent opportunity on record is Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, which solicits naloxone (an opioid-reversal medication) and safe drug deactivation systems—neither of which aligns with ziprasidone's scope. The county seeks 1,900 units of naloxone and 800 deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. This procurement represents community health and opioid-response spending, not antipsychotic pharmaceutical procurement, and signals either a tagging error in the opportunity database or minimal ziprasidone-specific solicitation activity at the state and local level.

The single traceable opportunity under this code provides no meaningful geographic or issuing-body pattern. Seminole County's naloxone-and-deactivation-systems IFB carries a response deadline of July 26, 2023—a date in the past relative to the current date of October 20, 2026. This code shows no active or recent state and local demand for ziprasidone mesilate as described, and the one posted record does not reflect ziprasidone procurement. Vendors pursuing this Commodity code should verify whether state mental-health agencies, correctional departments, or health systems post ziprasidone procurements under this code designation in their region, as the national record does not yet surface representative activity.